Sanofi
SNYHealthcareNASDAQDrug Manufacturers - General · Last scanned Jun 3, 2026
Scan Results
Daily timeframeSanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. The company carries a $102.45B market cap, placing it firmly in the large-cap category. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Market Cap
$102.45B
Beta
0.28
P/E (TTM)
18.53
P/E (Fwd)
8.09
EPS (TTM)
$2.31
EPS (Fwd)
$5.29
ROE
6.6%
ROA
4.7%
Cash
$5.54B
Total Debt
$20.02B
Free CF
$16.67B
52W Change
-13.5%
Annual Financials
Cash vs Debt
The company holds $5.54B in cash, though total debt stands at $20.02B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $16.67B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 6.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $40.56B to $46.72B.
SNY's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SNY.